BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34053383)

  • 21. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse.
    Mashima K; Oh I; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Fujiwara SI; Hatano K; Sato K; Omine K; Muroi K; Kanda Y
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e521-e527. PubMed ID: 30181104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
    Kitawaki T; Kadowaki N; Kondo T; Ishikawa T; Ichinohe T; Teramukai S; Fukushima M; Kasai Y; Maekawa T; Uchiyama T
    Am J Hematol; 2008 Apr; 83(4):315-7. PubMed ID: 18081032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia.
    Sun H; Li Y; Zhang ZF; Ju Y; Li L; Zhang BC; Liu B
    Int J Hematol; 2015 Nov; 102(5):579-86. PubMed ID: 26358057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
    Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
    ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Detection of WT1 gene in acute myeloid leukemia children by real-time fluorescent quantitative RT-PCR and its clinical significance].
    Zhang R; Sun HQ; Li G; Bai FY; Yang Y; Jing Q; Shi YJ; Yang JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):959-63. PubMed ID: 21867623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
    Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
    BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia.
    Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):958-66. PubMed ID: 23542687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
    Miyawaki S; Emi N; Mitani K; Oyashiki K; Kitamura K; Morishita T; Ogawa H; Komatsu N; Soma T; Tamaki T; Kosugi H; Ohnishi K; Mizoguchi H; Hiraoka A; Kodera Y; Ueda R; Morishima Y; Nakagawa M; Tobita T; Sugimoto K; Chiba S; Inoue N; Hamaguchi M; Koga D; Tamaki H; Naoe T; Sugiyama H; Takaku F
    Rinsho Ketsueki; 2005 Dec; 46(12):1279-87. PubMed ID: 16447800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
    Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
    Montesinos P; Bergua J; Infante J; Esteve J; Guimaraes JE; Sierra J; Sanz MÁ
    Ann Hematol; 2019 Nov; 98(11):2467-2483. PubMed ID: 31667544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia.
    Andersson C; Li X; Lorenz F; Golovleva I; Wahlin A; Li A
    Diagn Mol Pathol; 2012 Dec; 21(4):225-33. PubMed ID: 23111196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical significance of the alternative Wilms tumor gene overexpression-hypermethylation signature in acute myeloid leukemia.
    El Bordiny M; Al-Ghandour A; Abo Elwafa RA; Fayed O
    Clin Transl Oncol; 2019 Jul; 21(7):864-873. PubMed ID: 30506133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
    Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
    Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia.
    Sakamoto Y; Mariya Y; Sasaki S; Teshiromori R; Oshikiri T; Segawa M; Ogura K; Akagi T; Kubo K; Kaimori M; Funato T
    Tohoku J Exp Med; 2009 Oct; 219(2):169-76. PubMed ID: 19776535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.